<DOC>
	<DOC>NCT00180089</DOC>
	<brief_summary>The purpose of this study is to determine whether orale budesonide is effective in the prevention of acute gastrointestinal graft-versus-host disease (GVHD) following allogenic stem cell transplantation.</brief_summary>
	<brief_title>Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation</brief_title>
	<detailed_description>The purpose of this study is to determine whether orale budesonide is effective in the prevention of acute gastrointestinal graft-versus-host disease (GVHD) following allogenic stem cell transplantation.</detailed_description>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>planned allogenic stem cell or bone marrow transplantation HLA identity (max. 1 mismatch) standard GVHD prophylaxis with cyclosporin A or tacrolimus combined with MTX, +/ ATG or Campath1H written informed consent history of allogenic transplantation in vitro Tcell depleted transplant pretreatment with budesonide within the previous 4 weeks known intolerance to budesonide gastrointestinal infections portal hypertension concomitant infectious diseases liver cirrhosis, impaired liver function severe mental disorder lack of compliance drug or alcohol abuse pregnancy, lactation childbearing potential without effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>graft-versus-host disease</keyword>
	<keyword>budesonide</keyword>
	<keyword>stem cell transplantation</keyword>
</DOC>